Evaluation of Bismuth Oxide Nanoparticles (BiONPs) as a Potential Contrast Agent in Computed Tomography (CT) Imaging

Abstract:

The limitations of iodinated-based contrast media in computed tomography (CT) imaging have prompted studies into alternative contrast agents. Bismuth oxide nanoparticles (BiONPs) have emerged as a potential contrast agent due to their high X-ray attenuation, low toxicity, and cost-effectiveness. This study evaluates the efficacy of BiONPs as a contrast agent in CT imaging compared to traditional iodine-based contrast agents. A phantom study was conducted using synthesized BiONPs and iodine contrast agents (ICA) at a range of concentrations (0.05 to 1.0 mmol/L). The phantom was scanned with a CT scanner using 120 kVp tube potential and the contrast-to-noise ratio (CNR) was calculated to determine the contrast enhancement. The findings show that BiONPs demonstrated superior CNR values compared to iodine contrast agents at all concentrations tested. Specifically, at 0.5 mmol/L, BiONPs achieved a mean CNR of 161.70, significantly higher than iodine’s 51.47 (p < 0.05). Similar trends were observed at lower concentrations, with BiONPs consistently outperforming ICA. The findings highlight the BiONPs as an effective alternative to ICA, particularly at lower concentrations. This study highlights the capability of BiONPs to provide superior image contrast in CT imaging compared to conventional ICA. Its consistent performance across variations of concentration emphasizes its potential for improving diagnostic accuracy in CT imaging.

• Periodical: Materials Science Forum (Volume 1143)
• Pages: 31-37
• DOI: https://doi.org/10.4028/p-64hiIx
• Online since: December 2024
• Authors: Muhammad Hafiqrul Zuhair Husri, Suffian Mohamad Tajudin, Juliana Mohd Radzi, Nurul Syazwina Mohamed, Wan Nordiana Wan Abdul Rahman, Khairunisak Abdul Razak, Nur Hamizah Mohd Zainudin*
• Keywords: Bismuth Oxide Nanoparticles, Computed Tomography, Contrast-to-Noise Ratio, Image Contrast, Iodine Contrast Agent

References

[1] Jackson PA, Rahman WNWA, Wong CJ, Ackerly T, Geso M. Potential dependent superiority of gold nanoparticles in comparison to iodinated contrast agents. Eur J Radiol 2010;75:104–9.

DOI: 10.1016/j.ejrad.2009.03.057

[2] Algethami M, Feltis B, Geso M. Bismuth Sulfide Nanoparticles as a Complement to Traditional Iodinated Contrast Agents at Various X-Ray Computed Tomography Tube Potentials. Journal of Nanomaterials & Molecular Nanotechnology 2017;06:2–10.

DOI: 10.4172/2324-8777.1000222

[3] Winter H, Brown AL, Goforth AM. Bismuth-Based Nano- and Microparticles in X-Ray Contrast, Radiation Therapy, and Radiation Shielding Applications. Bismuth - Advanced Applications and Defects Characterization, 2018, p.71–90.

DOI: 10.5772/intechopen.76413

[4] Dadashi S, Poursalehi R, Delavari H. Optical and structural properties of oxidation resistant colloidal bismuth/gold nanocomposite: An efficient nanoparticles based contrast agent for X-ray computed tomography. J Mol Liq 2018;254:12–9.

DOI: 10.1016/j.molliq.2018.01.069

[5] Dadashi S, Poursalehi R, Delavari H H. In situ PEGylation of Bi nanoparticles prepared via pulsed Nd:YAG laser ablation in low molecular weight PEG: a potential X-ray CT imaging contrast agent. Comput Methods Biomech Biomed Eng Imaging Vis 2019;7:420–7.

DOI: 10.1080/21681163.2018.1452634

[6] Eladio J. Rivera, Tran LA, Hernández-Rivera M, Yoon D, Mikos AG, Rusakova IA, et al. Bismuth@US-tubes as a Potential Contrast Agent for X-ray Imaging Applications. J Mater Chem B Mater Biol Med 2013;1:1–21.

DOI: 10.1039/c3tb20742k

[7] Ahamed M, Akhtar MJ, Khan MAM, Alrokayan SA, Alhadlaq HA. Oxidative stress mediated cytotoxicity and apoptosis response of bismuth oxide (Bi2O3) nanoparticles in human breast cancer (MCF-7) cells. Chemosphere 2019;216:823–31.

DOI: 10.1016/j.chemosphere.2018.10.214

[8] Szostak K, Ostaszewski P, Pulit-Prociak J, Banach M. Bismuth Oxide Nanoparticles in Drug Delivery Systems. Pharm Chem J 2019;53:48–51.

DOI: 10.1007/s11094-019-01954-9

[9] Rajaee A, Wang S, Zhao L. Bismuth-based nanoparticles as radiosensitizer in low and high dose rate brachytherapy. Polish Journal of Medical Physics and Engineering 2019;25:79–85.

DOI: 10.2478/pjmpe-2019-0011

[10] Xuan Y, Song XL, Yang XQ, Zhang RY, Song ZY, Zhao DH, et al. Bismuth particles imbedded degradable nanohydrogel prepared by one-step method for tumor dual-mode imaging and chemo-photothermal combined therapy. Chemical Engineering Journal 2019;375:122000.

DOI: 10.1016/j.cej.2019.122000

[11] Naha PC, Zaki A Al, Hecht E, Chorny M, Chhour P, Yates DM, et al. Dextran coated bismuth-iron oxide nanohybrid contrast agents for computed tomography and magnetic resonance imaging. J Mater Chem B Mater Biol Med 2014;2:8239–48. https://doi.org/.

DOI: 10.1039/C4TB01159G

[12] Abidin SZ, Zulkifli ZA, Razak KA, Zin H, Yunus MA, Rahman WN. PEG coated bismuth oxide nanorods induced radiosensitization on MCF-7 breast cancer cells under irradiation of megavoltage radiotherapy beams. Mater Today Proc 2019;16:1640–5.

DOI: 10.1016/j.matpr.2019.06.029

[13] Zulkifli ZA, Razak KA, Rahman WNWA, Abidin SZ. Synthesis and Characterisation of Bismuth Oxide Nanoparticles using Hydrothermal Method: The Effect of Reactant Concentrations and application in radiotherapy. J Phys Conf Ser 2018;1082:1–7.

DOI: 10.1088/1742-6596/1082/1/012103

[14] J Fu J, Guo J, Qin A, Yu X, Zhang Q, Lei X, et al. Bismuth chelate as a contrast agent for X - ray computed tomography. J Nanobiotechnology 2020;18:1–10.

DOI: 10.1186/s12951-020-00669-4

[15] Dong YC, Hajfathalian M, Maidment PSN, Hsu JC, Naha PC, Si-Mohamed S, et al. Effect of Gold Nanoparticle Size on Their Properties as Contrast Agents for Computed Tomography. Sci Rep 2019;9:1–13.

DOI: 10.1038/s41598-019-50332-8

[16] Brown AL, Naha PC, Benavides-Montes V, Litt HI, Goforth AM, Cormode DP. Synthesis, X-ray opacity, and biological compatibility of ultra-high payload elemental bismuth nanoparticle X-ray contrast agents. Chemistry of Materials 2014;26:2266–74.

DOI: 10.1021/cm500077z

[17] Mohammadi M, Khademi S, Choghazardi Y, Irajirad R, Keshtkar M, Montazerabadi A. Modified Bismuth Nanoparticles: A New Targeted Nanoprobe for Computed Tomography Imaging of Cancer. Cell J 2022;24:515–21.

[18] Rizzo R, Capozza M, Carrera C, Terreno E. Bi-HPDO3A as a novel contrast agent for X-ray computed tomography. Sci Rep 2023;13:1–8.

DOI: 10.1038/s41598-023-43031-y

[19] Shu G, Zhang C, Wen Y, Pan J, Zhang X, Sun SK. Bismuth drug-inspired ultra-small dextran coated bismuth oxide nanoparticles for targeted computed tomography imaging of inflammatory bowel disease. Biomaterials 2024;311:122658.

DOI: 10.1016/j.biomaterials.2024.122658

[20] Rezaei MR, Khoshgard K, Hosseinzadeh L, Haghparast A, Eivazi MT. Application of dextran-coated iron oxide nanoparticles in enhancing the radiosensitivity of cancerous cells in radiotherapy with high-energy electron beams. J Cancer Res Ther 2019.

DOI: 10.4103/jcrt.JCRT_19_17

[21] Davenport MS, Perazella MA, Yee J, Dillman JR, Fine D, McDonald RJ, et al. Use of Intravenous Iodinated Contrast Media in Patients With Kidney Disease: Consensus Statements from the American College of Radiology and the National Kidney Foundation. Kidney Med 2020;2:85–93.

DOI: 10.1016/j.xkme.2020.01.001